Skip to content

Prednisolone in autism spectrum disorders

Prednisolone in regressive autism spectrum disorders: a randomized double-blind placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090117001556N102
Enrollment
50
Registered
2017-12-09
Start date
2017-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other Childhood Disintegrative disorder. Other childhood disintegrative disorder

Interventions

Intervention 1: Intervention group: Tablet Prednisolone( 1mg/kg per day) plus Risperidone ( 1 to 3.5 mg per day) for 12 weeks. Intervention 2: Control group: Tablet placebo plus Risperidone( 1 to 3.5
Treatment - Drugs
Placebo
Intervention group: Tablet Prednisolone( 1mg/kg per day) plus Risperidone ( 1 to 3.5 mg per day) for 12 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: clinical diagnosis of autistic Disorder according to DSM-5 criteria Children between ages of 3 and 12 years Regressive subtype according to ADI-R Presence of behavioral problems such as aggression, overactivity, or repetitive behaviors(indication of treatment with Risperidone)

Exclusion criteria

Exclusion criteria: presence of any active medical problem Any other psychiatric diagnosis except for Intellectual disability History of intolerance and allergy to corticosteroids History of Catarct History of peptic ulcer or Gastrointestinal bleeding Raise of ICP Hypertension Presence of neurological diseases including Fragile X syndrome, Angelman syndrome, Tuberous sclerosis

Design outcomes

Primary

MeasureTime frame
Severity of autism. Timepoint: Baseline and weeks 4, 8 and 12. Method of measurement: By Aberrant Behavior Checklist-Community( ABC-C) and Childhood Autism Rating scale( CARS).

Secondary

MeasureTime frame
IFN-?, IL-1ß, IL-8, IL-6, MCP-1, TGF-ß1. Timepoint: Baseline and week 12. Method of measurement: By ELISA.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026